Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Terminated Initiated Feb 6, 2013 (14 years ago)

Ciprofloxacin Tablets USP

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

Presence of Foreign Substance(s): A complaint was received for a rubber-like material in a 500 mg Ciprofloxacin tablet.

Cause type: Particulate / foreign matter

Visible foreign particles - glass, metal, fibers or other material - found in the product. Particles can enter from equipment wear, containers or the process, and are dangerous in injectables. All particulate / foreign matter recalls.

What was recalled

Ciprofloxacin Tablets USP, 500 mg, 100-count bottle, Rx only, Manufactured for West-ward Pharmaceutical Corp., Eatowntown, NJ 07724 by Hikma Pharmaceuticals, Amman, Jordan, NDC 0143-9928-01

Affected NDC 0143-9928-01

Compare with the code on your package — it is the most precise check available.

Drug: Ciprofloxacin Category: Antibiotic

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
Ciprofloxacin
NDC 00143-9928
HYDROCHLORIDE 500 mg/1 Tablet, Film Coated
Oral
Hikma Pharmaceuticals USA Inc. Rx
Recalling firm
West-ward Pharmaceutical Corp.
NDC code
0143-9928-01
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-220-2013 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall. This recall is now terminated, which means the firm has finished removing the affected product; anything on pharmacy shelves today should be unaffected.

Other Ciprofloxacin recalls

See all
Class II · Moderate risk

Ciprofloxacin Ophthalmic Solution USP

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 69315-308-05 D-0282-2025
Class II · Moderate risk

Ciprofloxacin Ophth Solution

Defective Container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect Direct Rx NDC 61919-795-05 D-0364-2025
Class II · Moderate risk

Ciprofloxacin Ophthalmic Solution USP

Defective container: Unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle

Ongoing Packaging defect FDC Limited NDC 69315-308-05 D-0182-2025
Class II · Moderate risk

Ciprofloxacin ophthalmic solution USP

Defective container: unable to get the solution out of the bottle as the spike of the cap was lodged in the nozzle of the product bottle.

Ongoing Packaging defect FDC Limited NDC 69315-308-10 D-0623-2024

Other recalls by West-ward Pharmaceutical Corp.

All 2013 recalls
Class II · Moderate risk

PredniSONE Tablets USP

Failed Tablet/Capsule Specifications: Discovery of an underweight tablet.

Terminated Failed specification West-Ward Pharmaceutical NDC 0054-4741-25 D-0008-2017
Class III · Low risk

Fentanyl Citrate Inj.

Failed Impurities/Degradation Specifications; 12 month stability testing (Expansion of RES #70548).

Terminated Impurity / degradation West-Ward Pharmaceutical Corp. NDC 0641-6028-25 D-1139-2015
Class III · Low risk

Fentanyl Citrate Inj.

Failed Impurities/Degradation Specifications; 12 month stability testing.

Terminated Impurity / degradation West-Ward Pharmaceutical Corporation NDC 0641-6028-25 D-0420-2015